Skip to main content
Equibles
WINT logo

WINT · Windtree Therapeutics Inc /De/

Track WINT — free

Use WINT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WINT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.14 +0.03 (+24.55%) At close · Aug 21
Rebalance outlook locked
Going-concern doubt — flagged Nov 19, 2025

Substantial doubt about the company's ability to continue as a going concern.

“We do not have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 19, 2025
Market Cap
$3,370
Shares
33.71M
Volume · Aug 21 6.7M Avg daily vol (3M) 12.02M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.14 Open$0.11 Day$0.09–0.16 52W close$0.11–551.50 Avg vol 30d14.6M Short int8K · 0.0% float · 1.0d Short vol57% Last earningsMay 5, 2022 DataMay 2020–Aug 2025 Filing10-Q · Nov 19

Up next

Latest filing: 10-Q
filed Nov 19, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$731,000
Trailing 12 months
Net income (TTM)
−$39.99M
Trailing 12 months
Revenue growth YoY
-85.0%
Year over year
Operating margin
-12,572.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+61.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −98%
below
Price vs 50-day avg −79%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −87%
trailing
6-month return −96%
trailing
YTD return −99%
this year
Relative strength −103%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $7 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.02% of float · ▼ -29.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
6 holders — near 3-yr low, contrarian setup
Fundamentals
Fair
Revenue growth −89%
Y/Y
EPS growth +68%
Y/Y
Free cash flow $-15.4M
Balance sheet $86.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 185%
annualized · 1-yr
Max drawdown −100%
past year
ATR 85.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−98% Bearish
Price vs 50-day avg
−79% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $1 › 200d $7 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.02% of float · ▼ -29.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $552
vs 200-day avg -98% vs 50-day avg -79%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
WINT
Windtree Therapeutics Inc /De/
this stock
$3,370 — -88.9% — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
6
% held
0.1%
Net QoQ
-28.3K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
7.7K
Days to cover
1.0d
Change
-3.2K sh
View
Short Volume
Short vol %
57%
As of
Aug 12, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$0
As of
Jun 18, 2026
View
Off-Exchange
Off-exchange %
70.6%
Week of
Aug 18, 2025
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$198.0K
Net income (FY)
$-1.8M
EPS diluted
$-1044900.00
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 22, 2026
This year
2
View
Earnings & Events
Webcasts
Last webcast
May 5, 2022
View

Performance

5D 20D 120D MTD YTD
WINT -73.5% -86.6% -95.7% -79.7% -99.2%
SPY -1.5% +0.2% +7.0% +0.6% +8.4%
vs SPY -72.0% -86.8% -102.7% -80.3% -107.7%
Key facts CIK 946486 CUSIP 97382D600 Visit website